Australia markets closed
  • ALL ORDS

    6,133.20
    -34.80 (-0.56%)
     
  • ASX 200

    5,927.60
    -32.70 (-0.55%)
     
  • AUD/USD

    0.7031
    +0.0001 (+0.01%)
     
  • OIL

    35.72
    -0.45 (-1.24%)
     
  • GOLD

    1,878.80
    +10.80 (+0.58%)
     
  • BTC-AUD

    19,193.41
    -63.08 (-0.33%)
     
  • CMC Crypto 200

    265.42
    +1.78 (+0.68%)
     
  • AUD/EUR

    0.6033
    +0.0015 (+0.25%)
     
  • AUD/NZD

    1.0623
    +0.0025 (+0.23%)
     
  • NZX 50

    12,084.47
    -117.33 (-0.96%)
     
  • NASDAQ

    11,052.95
    -297.80 (-2.62%)
     
  • FTSE

    5,577.27
    -4.48 (-0.08%)
     
  • Dow Jones

    26,501.60
    -157.51 (-0.59%)
     
  • DAX

    11,556.48
    -41.59 (-0.36%)
     
  • Hang Seng

    24,107.42
    -479.18 (-1.95%)
     
  • NIKKEI 225

    22,977.13
    -354.81 (-1.52%)
     

Novavax enters late-stage clinical trials

·1-min read
A vial with a potential coronavirus, COVID-19, vaccine at Novavax labs in Gaithersburg, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19
A vial with a potential coronavirus, COVID-19, vaccine at Novavax labs in Gaithersburg, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19

US biotech firm Novavax said Thursday it was initiating its final Phase 3 clinical trial for its experimental Covid-19 vaccine.

The trial will be carried out in the United Kingdom and aims to enroll 10,000 volunteers, aged 18-84, with and without underlying conditions, over the next four to six weeks.

"With a high level of SARS-CoV-2 transmission observed and expected to continue in the  UK, we are optimistic that this pivotal Phase 3 clinical trial will enroll quickly and provide a near-term view of NVX-CoV2373's efficacy," said Gregory Glenn, the company's president of research and development, using the technical name for the formulation.

It is the eleventh Covid-19 vaccine candidate to reach the Phase 3 stage globally.

The company has been awarded $1.6 billion by the US government to develop and fund the drug, which is administered by two intramuscular injections.

The Maryland-based company uses insect cells to grow synthesized pieces of the spike protein of the virus, which it hopes will evoke a robust human immune response.

It also uses an "adjuvant," a compound that boosts the production of neutralizing antibodies.

The company says the drug, which is a liquid formulation, can be stored at two degrees celsius to eight degrees celsius, refrigerator temperature.

In the spring, the company said it had proven the efficacy of a seasonal flu vaccine it had developed using the same technology.

ia/jh